Lantern Pharma, Inc. (LTRN)
| Market Cap | 90.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.22M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $14.34 |
| Previous Close | $14.51 |
| Change ($) | -0.17 |
| Change (%) | -1.17% |
| Day's Open | 14.40 |
| Day's Range | 13.77 - 14.75 |
| Day's Volume | 2,038,566 |
| 52-Week Range | 10.70 - 21.25 |
News
DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cance...
DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platfor...
About LTRN
Lantern Pharma, a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent... [Read more...]
| Industry Biotechnology | IPO Date Jun 11, 2020 |
| CEO Panna Sharma | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol LTRN |
Analyst Forecasts
According to 2 analysts, the average rating for Lantern Pharma stock is "Buy." The 12-month stock price forecast is 27.33, which is an increase of 90.59% from the latest price.